PTGX · Protagonist Therapeutics, Inc
$144.33
-5.17 (-3.46%)
At close · Aug 28
Market Cap
$9.39B
Shares
64.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$144.33
Open$147.73
Day$142.43–147.95
52W close$56.19–158.62
Avg vol 30d506K
Short int7.8M · 12.0% float · 16.4d
Short vol42%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Mar 21, 2027
Est · unconfirmed
· in 29 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+38%
above
Price vs 50-day avg
+4%
above
RSI (14)
48
neutral
MACD trend
Negative
52-week position
86%
near high
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+49%
trailing
YTD return
+65%
this year
Relative strength
+36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $138 › 200d $105 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +61 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.04% of float · ▲ +3.3% MoM · 16.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
346 holders — near 3-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
−89%
Y/Y
EPS growth
−148%
Y/Y
Free cash flow
$56.1M
Valuation
P/E 140.9
rich
Balance sheet
$23.2M
net cash
Quant / Vol
risk profile
Volatility
51%
annualized · 1-yr
Max drawdown
−16%
past year
ATR
4.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+38%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
86%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $138 › 200d $105 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +61 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.04% of float · ▲ +3.3% MoM · 16.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
346 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $56
Now $144 · 86%
Range high $159
vs 200-day avg +38%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTGX
this stock
Protagonist Therapeutics, Inc
|
$9.39B | +65.3% | -89.4% | 140.9 | 12.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +2.9% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTGX | -6.5% | +5.6% | +49.3% | +5.6% | +65.3% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -6.9% | +2.6% | +35.9% | +2.6% | +52.4% |
Key facts
CIK
1377121
CUSIP
74366E102
13F (30d)
287 filings
282 filers
Visit website
Investor relations